Safety, pharmacokinetic, and antitumor activity of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
文献类型：会议论文
| 作者 | Sun, Yongkun; Niu, Wei; Chi, Yihebali; Li, Chuan; Du, Chun-Xia; Li, Shuting; Wang, Jinwan; Li, Li; Wang, Fengqi |
| 出版日期 | 2015-05-20 |
| 卷号 | 33 |
| 期号 | 15 |
| 会议录 | JOURNAL OF CLINICAL ONCOLOGY
 |
| 会议录出版者 | AMER SOC CLINICAL ONCOLOGY |
| 文献子类 | Meeting Abstract |
| 语种 | 英语 |
| WOS研究方向 | Oncology |
| WOS记录号 | WOS:000358036902578 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/266127]  |
| 专题 | 中国科学院上海药物研究所 |
| 作者单位 | 1.Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China 2.Chinese Acad Medcl Sci, Canc Inst Hosp, Beijing, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Lab DMPK Res Herbal Med, Shanghai, Peoples R China 4.PUMC, Beijing, Peoples R China 5.CAMS, Canc Hosp, Dept Med Oncol, Beijing, Peoples R China |
| 推荐引用方式 GB/T 7714 | Sun, Yongkun,Niu, Wei,Chi, Yihebali,et al. Safety, pharmacokinetic, and antitumor activity of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.[C]. 见:. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。